President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.

The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help treat post-traumatic stress disorder.

Order calls on federal government to relax restrictions on psychedelics, including ibogaine, for potential treatments.

By Kamal Choudhury April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald Trump signed an executive order directing health regulators to speed up reviews ...

President Donald Trump signed an executive order that directs the FDA to accelerate their review of "psychedelics already designated as breakthrough therapy drugs." ...

Trump Targets Faster Access to Psychedelic Drugs for Mental Health. Here What That Means ...

The U.S. Food and Drug Administration has issued priority review vouchers for psilocybin and methylone therapies, and cleared the first U.S. ibogaine trial, following President Donald Trump’s ...

Read full article: Man critical after being shot during fight with son at Houston gas station, HPD says Inside NRG Stadium, crews are racing to replace the Texans’ turf with a world-class natural ...

The Food and Drug Administration said Friday it will offer ultra-fast review to three psychedelic drugs being developed to treat mental health conditions, including depression, the latest step by the ...